2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous environmental contaminant that is produced inadvertently during the synthesis of some organochlorine compounds, such as the chlorinated phenoxy pesticides. It is biologically and ecologically persistent, with an estimated half-life of 7 years in humans. It possesses high acute toxicity in rodents and is a carcinogen, teratogen, and immunotoxin. In chronic bioassays for carcinogenicity, TCDD at a dose of 10 ng/kg/day increases the incidence of liver tumors in female rats, making it one of the most potent animal carcinogens ever tested. A recent study in humans has shown an increase in the incidence of respiratory tract tumors in workers in chlorinated phenoxy herbicide plants. Considerable controversy and uncertainty remain, however, concerning its carcinogenic potency in humans and the reliability of using animal data to predict human risks.
Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is produced inadvertently during the synthesis of some organohalogen compounds, such as the herbicide 2,4,5-trichlorophenol, and is formed as a by-product of combustion of chlorine-containing wastes and during the bleaching ofpaper pulp during paper production. Over the last 20 years, this compound has received considerable attention FIGURE 1. Integrative approach for assessment of risk for exposure to dioxins. This approach attempts to incorporate data from exposures to dioxins in vivo and in vitro in both human and animal studies. PCB, polychlorinated biphenyl; PCDF, polychlorinated dibenzofuran; EGF, epidermal growth factor; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; EROD, ethoxyresorufin-O-deethylase; AHH, arylhydrocarbon hydroxylase.
response relationships for various effects. These issues are discussed in relation to the potential use of biomarkers (exposure, effect, and susceptibility) in evaluating potential adverse health effects in humans. Shown in Figure 1 is our integrative approach to assimilate data from human and animal studies following exposure both in vivo or in vitro to TCDD or its structural analogs. End points discussed include: a) evidence for carcinogenicity in epidemiological studies of accidentally exposed populations and in carcinogenicity studies in laboratory animals; b) biomarkers of exposure, including alterations of biochemical parameters in tissues from exposed human populations and from animal studies; and c) biomarkers of susceptibility after exposures of human and murine lymphocytes in vitro.
Evidence for Carcinogenicity of Dioxins from Human and Animal Studies Animal Carcinogenicity Data
There is convincing evidence that TCDD is a multisite carcinogen. In chronic bioassays for its carcinogenicity in rats, tumor incidences were increased at a number of sites. Available studies on TCDD carcinogenesis have been reviewed (4) and carcinogenic responses were seen after either long-term or short-term exposures to TCDD in every species studied. Tumors of various types have been induced in several organ systems, and these do not appear to be restricted to the site of application. In rats, TCDD induced neoplasms of the lung, oraVnasal cavities, thyroid, adrenal glands, and liver. In mice, TCDD caused neoplasms ofthe liver, subcutaneous tissue, and thyroid gland, and lung and thymic lymphomas. In hamsters, it produced squamous-cell carcinomas of the facial skin. Thmors of the integumentary system have been reported after oral (rats and mice), intraperitoneal (hamsters), and dermal (mice) exposures. TCDD is a trans-species (rat, hamster, mouse), trans-strain, trans-sex, multisite, complete carcinogen. It induced carcinogenic effects in laboratory animals at exposures as low as 0.01 ,ug/kg body weight/day in rat liver and 0.001 ,ug/kg/day in rat thyroid and is clearly among the most potent of all identified chemical carcinogens (4) .
TCDD is ineffective in short-term tests for genetic toxicity (5, 6) ; moreover, it does not bind covalently to DNA either in in vitro or in vivo, even when methods are used that can detect one adduct in 1011 normal nucleotides (7) . Therefore, TCDD is generally considered to be a nongenotoxic carcinogen; however, it may exert indirect genotoxic effects, as evidenced by one study in which TCDD increased the frequency of strand breaks in rat liver nuclei, possibly by increasing iron bioavailability and lipid peroxidation (8) .
There is strong evidence in experimental animal models that TCDD is a tumor promoter and not an initiator, although it must be kept in mind that the term "tumor promoter" is an operational rather than a mechanistic term. In multistage models for skin and liver cancer (9) (10) (11) , TCDD is a potent promoter but is virtually devoid of initiating activity.
Both hepatocellular carcinomas and adenomas were detected in a two-stage model for hepatocarcinogenesis in rats (a single initiating dose of N-nitrosodiethylamine followed by chronic exposure to 100 ng/kg/day TCDD). Interestingly, ovariectomy protected female rat liver from the tumor promoting actions of TCDD (12) . This finding is consistent with data from chronic bioassays which demonstrated that TCDD produces liver tumors in female but not in male rats (13) . The carcinogenicity data are also consistent with those on cell proliferation, which showed that TCDD increases cell proliferation rates in intact female rats but not in ovariectomized rats (12) . In contrast, ovariectomy sensitized rats to the tumor promoting actions of TCDD in lung (14) . These findings add to the growing amount of evidence that interactions of TCDD with hormonally mediated events are a critical component of the carcinogenic mechanisms of this chemical.
Human Cancer
Some reports in the literature indicate that exposure to phenoxyacetic acid herbicides, chlorophenols, and chlorinated dibenzodioxin contaminants, especially TCDD, may be associated with human cancer, including malignant lymphomas, soft-tissue sarcomas, thyroid tumors, lung tumors, and cancers at other sites (15) . The International Agency for Research on Cancer (IARC) (15) and the National Institute for Occupational Safety and Health (NIOSH) recently completed two pooled cohort studies. The NIOSH registry covered workers with possible exposure to TCDD during the manufacture/formation of 2,4,5-trichlorophenoxy acetic acid and 2,4,5-trichlorophenol. The IARC registry included workers exposed to all types of phenoxy acids and chlorophenols during manufacture and use.
The incidence of thyroid tumors was elevated in the IARC registry, and the risk was highest in workers with probable TCDD exposure. An increased risk for all cancers combined was observed in the NIOSH registry, and the risk increased with duration of exposure and latency. The NIOSH registry showed an increased incidence of respiratory tract cancers. Both the NIOSH and IARC registers reported a statistically nonsigniflcant increase in the incidence of soft-tissue sarcoma. Statistically significant increases in liver tumor incidences were seen in neither registry, which consisted primarily of men.
The human carcinogenicity data are consistent with the animal data in several respects. First, increased incidences of thyroid tumors were detected in both rats and humans. Second, liver tumor incidence was increased in neither male rats nor human males. Third, increases in lung tumor incidence were evident in the NIOSH registry and in male rats. Several issues confound human epidemiological studies on the carcinogenicity of TCDD. Exposures in the workplace occur as part of complex mixtures, so it is difficult to ascertain the role of TCDD in increasing tumor incidence. Also, humans are exposed daily to several ubiquitous, persistent structural analogs of dioxin, including the PCDFs and some polychlorinated biphenyls. Therefore, no true control population exists. Furthermore, there is increasing evidence of a great deal ofinterindividual variation in the magnitude of background exposures.
The environmental contamination episode in Seveso, Italy, in 1976 is a different exposure scenario than that represented by the IARC and NIOSH registries; the individuals in Seveso were exposed primarily to TCDD and not to the numerous other chemicals experienced by the NIOSH and IARC cohorts. Although the follow-up has been only 10-15 years and therefore of insufficient latency, some information on cancer mortality has been published. The standardized mortality ratios were elevated for certain cancers, including soft-tissue sarcoma, Hodgkin's disease, cancers of the gallbladder and bile duct, and thyroid and other endocrine-associated tumors (16) . These results are based on one to three deaths only, however, making it difficult to establish patterns relating tumor occurrence specifically to TCDD at this time.
Biomarkers for Exposure in Animals and Humans

Animal Studies
We have used a chronic exposure regimen in the context of a tumor promotion model with N-nitrosodiethylamine as the initiating agent and TCDD as the promoter in Sprague-Dawley rats to investigate dose-response relationships for biochemical responses and their association with carcinogenic processes. In these experiments, female rats received a single initiating dose of N-nitrosodiethylamine followed by chronic exposure to TCDD by gavage at doses ranging from 0.1 to 125 ng/kg/day for 30 weeks. Dose-response relationships for a number of biochemical responses following exposure to TCDD are summarized in Table 1 . One of the most sensitive biochemical markers for exposure to TCDD is induction of CYPlAl in the liver of exposed animals; exposures to as little as 0.1 ng/kg/day appear to produce detectable increases in CYPlAl activity. Mathematical evaluation of this data indicates that there is no apparent threshold for TCDDmediated induction of CYPlAl or CYP1A2 (17) . Downregulation of the binding of EGF (epidermal growth factor) to its receptor following TCDD exposure was another sensitive marker for TCDD-mediated effects, exhibiting an ED50 of 12 ng/kg/day, which is similar to the ED50s for CYPlAl and CYP1A2 induction. TCDD-mediated increases in cell proliferation, y-glutamyl transpeptidase-positive foci, and serum 5'-nucleotidase were less sensitive for detecting TCDD-mediated effects but may be more appro- priate markers for its carcinogenic effects. The concentrations of TCDD in liver were linearly related to the administered dose over the entire dose range.
Human Exposures
In Taiwan during 1979, a widespread poisoning incident occurred due to ingestion of rice oil contaminated with PCDFs. These compounds are structurally similar to TCDD and are thought to share the same mechanism of action: binding to the Ah receptor and induction of pleiotropic responses. Placentas from women exposed to contaminated rice oil were analyzed for EGF receptor binding and EGF-stimulated autophosphorylation as well as for CYPlAl activity; the data are displayed in Table 2 (18, 19) . The placentas from the exposed women showed decreased EGF receptor autophosphorylation activity although the number of binding sites was similar to that in control samples. The number of detectable binding sites for the glucocorticoid receptor was reduced in the exposed women to 42% of that in the control individuals. In rats and mice, glucocorticoid and EGF receptor binding is decreased by TCDD treatment (20, 21 (10, 22) . In certain strains of mice, TCDDmediated induction of CYPlAl segregates with a single genetic locus (Ah) (23) . The Ah locus has been postulated to contain the structural gene for the dioxin receptor. The first published evidence for involvement of the dioxin receptor in TCDD-dependent toxicity was an analysis of the dose-dependency, stereospecificity, and genetic segregation of TCDD-induced thymic atrophy and fetal abnormalities in two prototype inbred mouse strains (24) . Since publication of that report, many studies have established the involvement of the dioxin receptor in a variety of toxic responses elicited by TCDD, including epidermal hyperkeratinization in mice and humans and tumor-promoting activity in rodents. Most of the existing knowledge is largely correlative, however, and does not provide specific information on how this receptor functions to elicit the biochemical changes in target cells that lead to the observed pathological lesions.
Multiple complementation groups have been identified in the TCDD-dependent induction of CYP1A1, suggesting the involvement of more than one protein in this receptormediated response (25) . Recently, the complementary DNA and part of a gene for a protein (designated arnt) required for the cytosol-to-nucleus translocation of the TCDD-dioxin receptor complex in murine hepatoma cells were cloned (26) . The protein was found to contain significant homology to the consensus sequence for the basic (10) . Studies carried out in human squamous-cell carcinoma cell lines (27) (37) showed that exposure of murine B lymphocytes in vitro to nanomolar concentrations selectively inhibited antibody production. cells/mL in RPMI 1640 containing 2% phytohemagglutinin (Gibco, Grand Island, NY), 0.13% pokeweed mitogen (Gibco), 1 mM glutamine, and 5 x 10 -5 M 3-mercaptoethanol for 3 days at 37°C in a 5% CO2 atmosphere.
Human peripheral blood lymphocytes were isolated using Leucoprep tubes (Beckton Dickinson, Lincoln Park, NJ) by the manufacturers' suggested method. The cells were cultured at 1 x 106 cells/mL in RPMI 1640 containing 2% phytohemagglutinin, 0.13% pokeweed mitogen, and 1 mM glutamine for 3 days at 37°C in a 5% CO2 atmosphere. Cultured lymphocytes were exposed to various concentrations of TCDD absorbed into fetal calf serum, as previously described (34) . After 3 days in culture, the cells were assayed for EROD activity, as described by Thompson et al. (35) . bData represent mean ± SD for a cohort of 36 individuals; inducibility of EROD activity was replicated at least twice for each individual.
cData represent mean ± SD for five individual experiments.
Recently, Clark et al. (38) demonstrated that exposure to such concentrations in vitro resulted in the dosedependent stimulation of tyrosine kinase activity in murine lymphocytes. The finding that both human and murine lymphocytes respond to nanomolar concentrations of TCDD suggests that the two species respond similarly. Another important consideration for assessing human risk for TCDD-mediated effects is interindividual differences in response, perhaps related to genetic susceptibility. As discussed above, the Ah receptor appears to regulate differences in susceptibility to TCDD-mediated effects in various strains of mice. Humans also demonstrate interindividual differences in their responsiveness to TCDD and related compounds. We have analyzed CYPlAl induction by quantifying EROD activity in lymphocytes from a cohort of 36 individuals. Interindividual variation in maximal induction of EROD activity by TCDD is shown in Figure 2 . The responses fall into an essentially bimodal or perhaps trimodal distribution, with approximately 70% of the individuals having a low response and 30% responding with a high maximal EROD response. This finding may be due to genetic differences in the capacity of human cells to be induced by TCDD. A number of investigators have suggested that a high inducibility phenotype for AHH induction may be associated with increased susceptibility to lung cancer (39) (40) (41) . Induction of EROD activity in human lymphocytes in vitro may therefore be useful for phenotyping individuals for susceptibility to adverse human health effects following exposure to TCDD or polycyclic aromatic hydrocarbons.
We have attempted to characterize inducibility phenotypes further with restriction fragment length polymorphism (RFLP) genotype analysis. Kawajiri et al. (42) recently described an MspI polymorphism in the 3' noncoding region of the CYPlAl gene that was associated with increased risk for lung cancer. Petersen et al (43) reported that in one family heterozygosity for this poly- In mice, allelic differences in the Ali receptor result in strains with different susceptibilities to the toxic and biochemical effects of TCDD (10, 44) . We are analyzing human lymphocytes for levels of Ah receptor protein, using photoaffinity ligands for the receptor, to deter mine if there is an association between high inducibility and All receptor levels. Figure 3 is (14, 48) . Such a situation may exist for induction CfCYPlA1 and CYP1A2. For example, extrapolation of data on CYPlAl or CYP1A2 induction in our rat tumor promotion model gives no evidence of a threshold. Therefore, if CYPlAl is used as a surrogate for TCDD-mediated cancer dose-response relationships, then the ADI (one cancer in 106 individuals) would be similar to the current U.S. standard of 6 fg/kg/day (49) . If a threshold model is employed in which CYPlAl induction is used as a surrogate for cancer, the following considerations emerge. The current lowest detectable dose for inducing CYPlAl in rat liver is 100 pg/kg/day (Table 1) ; we have preliminary data, using a polymerase chain reaction method, that the lowest detectable dose for CYPlAl induction could be as low as 10 pg/kg/day. If a 100-fold safety factor were employed, the ADI would be 100 fg/kg/day; if a 1000-fold safety factor were used, it would 10 fg/kg/day.
One of the key issues in risk assessment is the relevance of the animal data for estimating human risks. In the case of TCDD, our data provide strong evidence that humans respond similarly to rats for many biochemical effects, including CYPlAl induction. Although using CYPlAl induction as a surrogate marker for cancer is simple and attractive, the approach may be flawed. For example, we have shown that dose-response relationships for TCDDmediated increases in hepatic cell proliferation and preneoplastic lesions are very different from those for CYPlAl induction. Increases in cell proliferation are detected at much higher doses than those needed to produce enzyme induction (lable 1). Analysis of the rat tumor data suggests that CYPlAl induction may not be a good predictor of liver tumors. Finally, most TCDD risk assessments have focused on cancer risk, whereas additional toxic responses, such as teratogenesis and immunotoxicity, should also be included in risk assessment models for TCDD.
